Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count

Autor:	Alexia Plocque, Julien Broséus, Margaux Sevin, Laurent Voillat, Marion Divoux, Pierre Feugier, Agnès Guerci-Bresler, François Girodon
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis Red Blood Cell Transfusion lenalidomide lcsh:Medicine Case Report Context (language use) thrombocytosis Case Reports Ring sideroblasts 030204 cardiovascular system & hematology myeloproliferative syndrome 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Platelet Lenalidomide lcsh:R5-920 Thrombocytosis business.industry lcsh:R food and beverages General Medicine medicine.disease myelodysplastic syndrome 030220 oncology & carcinogenesis business lcsh:Medicine (General) medicine.drug
Zdroj:	Clinical Case Reports, Vol 8, Iss 9, Pp 1774-1780 (2020) Clinical Case Reports
ISSN:	2050-0904
Popis:	Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN‐RS‐T in the context of major platelet counts.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8647ec9d088c8286a51f3ce4782785 https://doaj.org/article/4eb955fadf304ab59a650483cda4cf8a Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.